Dimension

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to radically improve lives. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological and chemical datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained

Modal Labs provides high-performance AI infrastructure designed to facilitate the development and deployment of applications for data, AI, and machine learning. Their platform allows developers to run inference, training, and batch processing with instant autoscaling and a seamless developer experience.

Enveda Bio leverages evolutionary intelligence for drug discovery, utilizing a large foundation model called PRISM for analyzing small molecule mass spectra.

Monte Rosa Therapeutics is focused on developing molecular glue degraders (MGDs) that target undruggable proteins for therapeutic purposes, particularly in immunology and inflammation.

Aspect Biosystems is a biotechnology company pioneering the development of bioprinted tissue therapeutics to transform how we treat some of the most elusive diseases. Aspect's bioprinted tissue therapeutics are designed to replace, repair, or supplement biological function inside the body.

NewLimit is a biotechnology company focused on extending human healthspan through epigenetic reprogramming, developing medicines to treat aging and related diseases.

Automata Technologies is a leading automation company powering life sciences labs with its LINQ platform, which automates lab workflows and is designed to be easily adoptable by various research institutions and pharmaceutical companies.

Kimia Therapeutics is focused on generating a chemical atlas for treating human diseases using advanced technologies that combine machine learning with chemical design and synthesis.

Convoke is a modern recovery management system in a single, secure SaaS platform. Convoke enables creditors to increase recovery rates, reduce the burden of third-party oversight, and ensure regulatory compliance.

Kaleidoscope Bio provides solutions to accelerate R&D workflows for internal and CRO projects, optimizing experiment and FTE spend for complex programs.

Lamin is an open data framework for biology that allows users to query, trace, and validate datasets and models at scale, automating context for agents and humans.

Bioscience investor translating grant-funded research into venture-scale companies, with a pipeline centered on engineering biology using robotic cloud labs and computational design for human health and planetary sustainability. The firm grew directly out of a philanthropic grants program at the Thiel Foundation that funded highly speculative science before spinning into a traditional venture fund.

Originating from a quantitative hedge fund, Two Sigma Ventures uses quant models and embeds data scientists, engineers, and researchers to tackle ML and data-pipeline challenges for AI, software infrastructure, and hardtech. The fund uses quantitative models and data science to support investment decisions and focuses specifically on companies that exploit the compounding of data and computing power, particularly in AI/ML, advanced software infrastructure, and hardtech at the intersection of climate, manufacturing, and life sciences.

Flagship Pioneering operates as an "institutional innovation" model that internally originates 80-100 "explorations" per year through Flagship Labs based on "What if…?" hypotheses, then systematically evolves promising ideas through a staged company-creation funnel (Explorations → ProtoCos → NewCos → GrowthCos) that it fully founds, funds, and owns through early stages. The firm positions itself as principal founder rather than a traditional investor, building "bioplatform" companies organized around proprietary discovery engines and operating its own drug development unit, Pioneering Medicines, which partners directly with large pharmas like Pfizer and Novo Nordisk to co-create therapeutics.

Founded in 2002, +ND invests in disruptive technologies spanning life, physical, and data sciences, prioritizing opportunities driven by scientific convergence.

Invests in disruptive, technology-focused startups; established in 1999.